2nw4 › Citations

Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats.

Ostrowski J, Kuhns JE, Lupisella JA, Manfredi MC, Beehler BC, Krystek SR, Bi Y, Sun C, Seethala R, Golla R, Sleph PG, Fura A, An Y, Kish KF, Sack JS, Mookhtiar KA, Grover GJ, Hamann LG
Endocrinology 148 4-12 (2007)
Cited: 53 times
EuropePMC logo PMID: 17008401

Abstract

A novel, highly potent, orally active, nonsteroidal tissue selective androgen receptor (AR) modulator (BMS-564929) has been identified, and this compound has been advanced to clinical trials for the treatment of age-related functional decline. BMS-564929 is a subnanomolar AR agonist in vitro, is highly selective for the AR vs. other steroid hormone receptors, and exhibits no significant interactions with SHBG or aromatase. Dose response studies in castrated male rats show that BMS-564929 is substantially more potent than testosterone (T) in stimulating the growth of the levator ani muscle, and unlike T, highly selective for muscle vs. prostate. Key differences in the binding interactions of BMS-564929 with the AR relative to the native hormones were revealed through x-ray crystallography, including several unique contacts located in specific helices of the ligand binding domain important for coregulatory protein recruitment. Results from additional pharmacological studies effectively exclude alternative mechanistic contributions to the observed tissue selectivity of this unique, orally active androgen. Because concerns regarding the potential hyperstimulatory effects on prostate and an inconvenient route of administration are major drawbacks that limit the clinical use of T, the potent oral activity and tissue selectivity exhibited by BMS-564929 are expected to yield a clinical profile that provides the demonstrated beneficial effects of T in muscle and other tissues with a more favorable safety window.

Articles - 2nw4 mentioned but not cited (2)

  1. Optimization of Protein-Ligand Electrostatic Interactions Using an Alchemical Free-Energy Method. Wade AD, Huggins DJ. J Chem Theory Comput 15 6504-6512 (2019)
  2. Computational Analysis of Residue-Specific Binding Free Energies of Androgen Receptor to Ligands. Shao G, Bao J, Pan X, He X, Qi Y, Zhang JZH. Front Mol Biosci 8 646524 (2021)


Reviews citing this publication (21)

  1. Protective actions of sex steroid hormones in Alzheimer's disease. Pike CJ, Carroll JC, Rosario ER, Barron AM. Front Neuroendocrinol 30 239-258 (2009)
  2. Sex hormones, aging, and Alzheimer's disease. Barron AM, Pike CJ. Front Biosci (Elite Ed) 4 976-997 (2012)
  3. Androgen cell signaling pathways involved in neuroprotective actions. Pike CJ, Nguyen TV, Ramsden M, Yao M, Murphy MP, Rosario ER. Horm Behav 53 693-705 (2008)
  4. Selective androgen receptor modulators as function promoting therapies. Bhasin S, Jasuja R. Curr Opin Clin Nutr Metab Care 12 232-240 (2009)
  5. Nuclear receptor drug discovery. Chen T. Curr Opin Chem Biol 12 418-426 (2008)
  6. Selective androgen receptor modulators in preclinical and clinical development. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Nucl Recept Signal 6 e010 (2008)
  7. Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity. Yarrow JF, McCoy SC, Borst SE. Steroids 75 377-389 (2010)
  8. Recent developments in antiandrogens and selective androgen receptor modulators. Haendler B, Cleve A. Mol Cell Endocrinol 352 79-91 (2012)
  9. Deciphering the selective androgen receptor modulators paradigm. Zhang X, Sui Z. Expert Opin Drug Discov 8 191-218 (2013)
  10. Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase? Gao W, Dalton JT. Mol Interv 7 10-13 (2007)
  11. Update on emerging drugs for sarcopenia - age-related muscle wasting. Lynch GS. Expert Opin Emerg Drugs 13 655-673 (2008)
  12. Androgen receptor as a therapeutic target. Gao W. Adv Drug Deliv Rev 62 1277-1284 (2010)
  13. New selective estrogen and androgen receptor modulators. Clarke BL, Khosla S. Curr Opin Rheumatol 21 374-379 (2009)
  14. Actin associated proteins function as androgen receptor coregulators: an implication of androgen receptor's roles in skeletal muscle. Ting HJ, Chang C. J Steroid Biochem Mol Biol 111 157-163 (2008)
  15. Recent advances in the development of selective androgen receptor modulators. Zhang X, Lanter JC, Sui Z. Expert Opin Ther Pat 19 1239-1258 (2009)
  16. Review of health risks of low testosterone and testosterone administration. Jia H, Sullivan CT, McCoy SC, Yarrow JF, Morrow M, Borst SE. World J Clin Cases 3 338-344 (2015)
  17. Medicinal Use of Testosterone and Related Steroids Revisited. Tauchen J, Jurášek M, Huml L, Rimpelová S. Molecules 26 1032 (2021)
  18. Novel Uses for the Anabolic Androgenic Steroids Nandrolone and Oxandrolone in the Management of Male Health. Wu C, Kovac JR. Curr Urol Rep 17 72 (2016)
  19. Androgen receptor modulators: a marriage of chemistry and biology. McEwan IJ. Future Med Chem 5 1109-1120 (2013)
  20. The Therapeutic Intervention of Sex Steroid Hormones for Sarcopenia. Huang LT, Wang JH. Front Med (Lausanne) 8 739251 (2021)
  21. [Myoanabolic steroids and selective androgen receptor modulators: mechanism of action and perspectives]. Tóth M. Orv Hetil 150 2051-2059 (2009)

Articles citing this publication (30)

  1. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. Askew EB, Gampe RT, Stanley TB, Faggart JL, Wilson EM. J Biol Chem 282 25801-25816 (2007)
  2. Triclocarban enhances testosterone action: a new type of endocrine disruptor? Chen J, Ahn KC, Gee NA, Ahmed MI, Duleba AJ, Zhao L, Gee SJ, Hammock BD, Lasley BL. Endocrinology 149 1173-1179 (2008)
  3. Androgens regulate neprilysin expression: role in reducing beta-amyloid levels. Yao M, Nguyen TV, Rosario ER, Ramsden M, Pike CJ. J Neurochem 105 2477-2488 (2008)
  4. Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands. Norris JD, Joseph JD, Sherk AB, Juzumiene D, Turnbull PS, Rafferty SW, Cui H, Anderson E, Fan D, Dye DA, Deng X, Kazmin D, Chang CY, Willson TM, McDonnell DP. Chem Biol 16 452-460 (2009)
  5. Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Osguthorpe DJ, Hagler AT. Biochemistry 50 4105-4113 (2011)
  6. Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones. van Oeveren A, Pio BA, Tegley CM, Higuchi RI, Wu M, Jones TK, Marschke KB, Negro-Vilar A, Zhi L. Bioorg Med Chem Lett 17 1523-1526 (2007)
  7. Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors. Petit-Topin I, Fay M, Resche-Rigon M, Ulmann A, Gainer E, Rafestin-Oblin ME, Fagart J. J Steroid Biochem Mol Biol 144 Pt B 427-435 (2014)
  8. Tissue selectivity of the anabolic steroid, 19-nor-4-androstenediol-3beta,17beta-diol in male Sprague Dawley rats: selective stimulation of muscle mass and bone mineral density relative to prostate mass. Page ST, Marck BT, Tolliver JM, Matsumoto AM. Endocrinology 149 1987-1993 (2008)
  9. A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats. Allan GF, Tannenbaum P, Sbriscia T, Linton O, Lai MT, Haynes-Johnson D, Bhattacharjee S, Zhang X, Sui Z, Lundeen SG. Endocrine 32 41-51 (2007)
  10. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. Vajda EG, López FJ, Rix P, Hill R, Chen Y, Lee KJ, O'Brien Z, Chang WY, Meglasson MD, Lee YH. J Pharmacol Exp Ther 328 663-670 (2009)
  11. Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. Miller CP, Shomali M, Lyttle CR, O'Dea LS, Herendeen H, Gallacher K, Paquin D, Compton DR, Sahoo B, Kerrigan SA, Burge MS, Nickels M, Green JL, Katzenellenbogen JA, Tchesnokov A, Hattersley G. ACS Med Chem Lett 2 124-129 (2011)
  12. Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones. van Oeveren A, Motamedi M, Martinborough E, Zhao S, Shen Y, West S, Chang W, Kallel A, Marschke KB, López FJ, Negro-Vilar A, Zhi L. Bioorg Med Chem Lett 17 1527-1531 (2007)
  13. Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators. Hamann LG, Manfredi MC, Sun C, Krystek SR, Huang Y, Bi Y, Augeri DJ, Wang T, Zou Y, Betebenner DA, Fura A, Seethala R, Golla R, Kuhns JE, Lupisella JA, Darienzo CJ, Custer LL, Price JL, Johnson JM, Biller SA, Zahler R, Ostrowski J. Bioorg Med Chem Lett 17 1860-1864 (2007)
  14. Muscle-bound? A tissue-selective nonsteroidal androgen receptor modulator. Wilson EM. Endocrinology 148 1-3 (2007)
  15. Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part I. Aikawa K, Miyawaki T, Hitaka T, Imai YN, Hara T, Miyazaki J, Yamaoka M, Kusaka M, Kanzaki N, Tasaka A, Shiraishi M, Yamamoto S. Bioorg Med Chem 23 2568-2578 (2015)
  16. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. Piu F, Gardell LR, Son T, Schlienger N, Lund BW, Schiffer HH, Vanover KE, Davis RE, Olsson R, Bradley SR. J Steroid Biochem Mol Biol 109 129-137 (2008)
  17. Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. Mosure SA, Shang J, Eberhardt J, Brust R, Zheng J, Griffin PR, Forli S, Kojetin DJ. J Med Chem 62 2008-2023 (2019)
  18. Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators. Manfredi MC, Bi Y, Nirschl AA, Sutton JC, Seethala R, Golla R, Beehler BC, Sleph PG, Grover GJ, Ostrowski J, Hamann LG. Bioorg Med Chem Lett 17 4487-4490 (2007)
  19. A selective androgen receptor modulator with minimal prostate hypertrophic activity restores lean body mass in aged orchidectomized male rats. Allan G, Sbriscia T, Linton O, Lai MT, Haynes-Johnson D, Bhattacharjee S, Ng R, Sui Z, Lundeen S. J Steroid Biochem Mol Biol 110 207-213 (2008)
  20. Analysis of selective androgen receptor modulators by gas chromatography-microchip atmospheric pressure photoionization-mass spectrometry. Luosujärvi L, Haapala M, Thevis M, Saarela V, Franssila S, Ketola RA, Kostiainen R, Kotiaho T. J Am Soc Mass Spectrom 21 310-316 (2010)
  21. Function-regulating pharmacophores in a sulfonamide class of glucocorticoid receptor agonists. Kuzmich D, Bentzien J, Betageri R, DiSalvo D, Fadra-Khan T, Harcken C, Kukulka A, Nabozny G, Nelson R, Pack E, Souza D, Thomson D. Bioorg Med Chem Lett 23 6640-6644 (2013)
  22. Improving selective androgen receptor modulator discovery and preclinical evaluation. Jones JO. Expert Opin Drug Discov 4 981-993 (2009)
  23. Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate. Aikawa K, Asano M, Ono K, Habuka N, Yano J, Wilson K, Fujita H, Kandori H, Hara T, Morimoto M, Santou T, Yamaoka M, Nakayama M, Hasuoka A. Bioorg Med Chem 25 3330-3349 (2017)
  24. Predicting the Activation of the Androgen Receptor by Mixtures of Ligands Using Generalized Concentration Addition. Schlezinger JJ, Heiger-Bernays W, Webster TF. Toxicol Sci 177 466-475 (2020)
  25. Structural basis for computational screening of non-steroidal androgen receptor ligands. Nyrönen TH, Söderholm AA. Expert Opin Drug Discov 5 5-20 (2010)
  26. Substituted phenyl as a steroid A-ring mimetic: providing agonist activity to a class of arylsulfonamide nonsteroidal glucocorticoid ligands. DiSalvo D, Kuzmich D, Bentzien J, Regan J, Kukulka A, Fadra-Khan T, Nelson R, Harcken C, Thomson D, Nabozny G. Bioorg Med Chem Lett 23 6645-6649 (2013)
  27. Ex vivo development of the entire mouse fetal reproductive tract by using microdissection and membrane-based organ culture techniques. Jia S, Zhao F. Differentiation 123 42-49 (2022)
  28. Lead evaluation of tetrahydroquinolines as nonsteroidal selective androgen receptor modulators for the treatment of osteoporosis. Nagata N, Furuya K, Oguro N, Nishiyama D, Kawai K, Yamamoto N, Ohyabu Y, Satsukawa M, Miyakawa M. ChemMedChem 9 197-206 (2014)
  29. A Combinatorial Regulatory Platform Determines Expression of RNA Polymerase III Subunit RPC7α (POLR3G) in Cancer. Cheng R, Zhou S, K C R, Lizarazo S, Mouli L, Jayanth A, Liu Q, Van Bortle K. Cancers (Basel) 15 4995 (2023)
  30. Small-Molecule Inhibition of Androgen Receptor Dimerization as a Strategy against Prostate Cancer. Fu W, Yang H, Hu C, Liao J, Gong Z, Zhang M, Yang S, Ye S, Lei Y, Sheng R, Zhang Z, Yao X, Tang C, Li D, Hou T. ACS Cent Sci 9 675-684 (2023)


Quick links